These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27752776)

  • 1. Comparison of HE4 and CA125 levels in women with benign gynecologic disorders : Does age or menopausal status matter?
    Delić R; Štefanović M; Krivec Š; Weber V; Koren J
    Wien Klin Wochenschr; 2016 Dec; 128(Suppl 7):543-547. PubMed ID: 27752776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
    Moore RG; Miller MC; Steinhoff MM; Skates SJ; Lu KH; Lambert-Messerlian G; Bast RC
    Am J Obstet Gynecol; 2012 Apr; 206(4):351.e1-8. PubMed ID: 22284961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass.
    Huang X; Wang Y; He X; Kang F; Luo L; Su Z; Ye H
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
    Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
    Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
    Zhang Y; Qiao C; Li L; Zhao X; Li Y
    Afr Health Sci; 2014 Dec; 14(4):913-8. PubMed ID: 25834501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
    Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
    Abdalla N; Piorkowski R; Bachanek M; Stanirowski P; Cendrowski K; Sawicki W
    Dis Markers; 2018; 2018():5289804. PubMed ID: 29849823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
    Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
    Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HE4 a biomarker of ovarian cancer].
    Presl J; Kučera R; Topolčan O; Novotný Z; Vrzalová J; Fuchsova R; Betincová L; Rokyta Z
    Ceska Gynekol; 2012 Oct; 77(5):445-9. PubMed ID: 23116350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.
    Li PL; Zhang X; Li TF; Wang LL; Du LT; Yang YM; Li J; Wang HY; Zhang Y; Wang CX
    Clin Chim Acta; 2015 Jan; 439():148-53. PubMed ID: 25445414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
    Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
    Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy and Optimal Cutoff Value of Serum HE4 to Predict Ovarian Cancer in Thai Women with Pelvic Masses.
    Yanaranop M; Tiyayon J; Nakrangsee S; Thinkhamrop B
    J Med Assoc Thai; 2016 Dec; 99(12):1263-71. PubMed ID: 29952496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N; Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma.
    Mi D; Zhang YX; Wang CJ; Feng Q; Qi P; Chen SQ
    J Obstet Gynaecol Res; 2016 Oct; 42(10):1326-1335. PubMed ID: 27307153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HE4 and ROMA index in Czech postmenopausal women.
    Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
    Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
    Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
    Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker.
    Machida H; Hirakawa T; Tsunekawa K; Kimura T; Murakami M; Abe Y
    Gynecol Obstet Invest; 2023; 88(6):349-358. PubMed ID: 37788640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.